Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Nutrients|October 31, 2015
Association between Dietary Vitamin A Intake and the Risk of Glioma: Evidence from a Meta-analysisWen Lv, Xian Zhong, Lingmin Xu, et al.
Chemical Communications (Cambridge, England)|March 24, 2012
CoBr2-TMTU-zinc catalysed-Pauson-Khand reactionYuefan Wang, Lingmin Xu, Ruocheng Yu, et al.
The Journal of Organic Chemistry|May 3, 2013
Highly regioselective syntheses of substituted triphenylenes from 1,2,4-trisubstituted arenes via a co-catalyzed intermolecular alkyne cyclotrimerizationLingmin Xu, Ruocheng Yu, Yuefan Wang, et al.
The Journal of Physical Chemistry Letters|July 27, 2026
Complementary Chalcogen Ordering Enables Energetically Favorable and Multifunctional Two-Dimensional Transition-Metal DichalcogenidesLingmin Xu, Zhen Gao, Fengxian Ma, et al.
Molecular Medicine Reports|November 21, 2017
Semi‑random mutagenesis profile of BCR‑ABL during imatinib resistance acquirement in K562 cellsYan Dong, Xiaotong Gao, Yingxin Zhao, et al.
Cancer Pathogenesis and Therapy|April 11, 2024
Next-generation sequencing reveals relapse and leukemia-free survival risks in newly diagnosed acute myeloid leukemia treated with CAG regimen combined with decitabineSai Huang, Peng Chen, Lu Wang, et al.
Trials|June 6, 2022
Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trialLiping Dou, Bo Peng, Xin Li, et al.
Frontiers in Immunology|March 13, 2025
Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemiaQingyang Liu, Jingjing Yang, Lei Lv, et al.
Clinical and Experimental Medicine|June 3, 2026
Venetoclax, azacitidine, and chidamide in combination with cytarabine, aclarubicin, and G-CSF as induction chemotherapy for myelodysplasia-related acute myeloid leukemiaLei Lv, Jingjing Yang, Qingyang Liu, et al.
Annals of Hematology|November 24, 2021
Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapyJingjing Yang, Bo Peng, Lu Wang, et al.
Pageof 2